Clinical Trial Update: Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label dose-escalation study of IONIS-STAT3Rx in patients with advanced cancers, including diffuse large B-cell lymphoma, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Diffuse Large B-cell Lymphoma
• Lymphoma

Drugs mentioned

• IONIS-STAT3Rx

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Advanced Cancers, DLBCL | Phase 1, Phase 2 | Status: COMPLETED